A report from the Genetic Engineering & Biotechnology News or GEN website revealed its top 30 venture capital companies for 2013. The list includes the venture capital firms and broader financial companies who had poured the most money into biotechnology and pharmaceutical firms. The firms are ranked in terms of total capital under management or the total active committed capital from the funds in use.

Aside from the list of top 30 investment firms, the list also includes more firms that have funds that total over USD 1.1 billion as compared to the list last year, GEN said. Most of the information was derived from the companies themselves. The top ten venture capital firms that have made it to GEN's top 30 list are given in the paragraphs that follow.

The top venture capital firm for biotech and pharmaceutical startups is New Enterprise Associates. According to GEN, New Enterprise has committed USD 13 billion in capital in 14 funds. Following New Enterprise is Kleiner Perkins Caufield and Byers with over USD 7 billion in assets under management. It is spread out in 15 funds. On third place is OrbiMed Advisors. It has over USD 8 billion in five public funds. It also has private equity funds in North America and Europe, Asia and Israel and a Royal Opportunities Fund. Fourth on the list is Bessemer Venture Partners with over USD 4 billion in assets under management in eight funds. Polaris Venture Partners is on fifth place. It has USD 3.5 billion under management in six funds.

On sixth place is Highland Capital Partners with close to USD 3.5 billion under management in 11 funds. Canaan Partners is on seventh place, with USD 3.4 billion under management in nine funds. Index Ventures is on 8th on the list. It has USD 3.25 billion in total committed capital in mixed and dedicated funds. Number 9 on the list is Atlas Ventures, which has over USD 3 billion in committed capital in nine funds. Rounding up the top ten is InterWest Partners. It has USD 2.8 billion under management in 10 funds.